A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

被引：0
作者：
Ye Q. [1 ]
He X.-O. [2 ]
D’Urzo A. [3 ]
机构：
[1] John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI
[2] Faculty of Medicine, University of Manitoba, Winnipeg, MB
[3] Department of Family and Community Medicine, University of Toronto, Toronto, ON
来源：
Pulmonary Therapy | 2017年 / 3卷 / 1期
关键词：
Add on therapy; Airway inflammation; Asthma; Dose–response; Efficacy; Inhaled corticosteroids; Mechanism of action; Pathophysiology; Safety; Side effects;
D O I：
10.1007/s41030-017-0043-5
中图分类号：
学科分类号：
摘要：
Asthma is a chronic inflammatory disease characterized by symptoms of cough, dyspnea, chest tightness, and wheeze. Inhaled corticosteroids (ICS) have been recommended as initial therapy in the treatment of persistent asthma in all guidelines, as they have been shown to reduce morbidity and mortality. However, high-dose regimens and long-term use of ICS may be associated with a variety of side effects, similar to those observed with systemic corticosteroid therapy. These side effects include impaired growth in children, osteoporosis, fractures, glaucoma, cataracts, and skin thinning. The current recommendations on ICS use in asthma management will be reviewed in this article with a view to highlight treatment strategies that strike an optimal balance between safety and efficacy. © 2017, The Author(s).
引用
收藏
页码：1 / 18
页数：17
相关论文
共 165 条
  • [61] Hawkins G., McMahon A.D., Twaddle S., Wood S.F., Ford I., Thomson N.C., Stepping down inhaled corticosteroids in asthma: a randomized controlled trial, BMJ, 326, (2003)
  • [62] Papi A., Canonica G.W., Maestrelli P., Et al., Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma, N Engl J Med, 356, pp. 2040-2052, (2007)
  • [63] Randomized comparison of strategies for reducing treatment in mild persistent asthma, N Engl J Med, 356, pp. 2027-2039, (2007)
  • [64] Tonelli M., Bacci E., Dente F.L., Et al., Predictors of symptom recurrence after lose-dose inhaled corticosteroid cessation in mild persistent asthma, Respir Med, 100, pp. 622-629, (2006)
  • [65] Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., Koskela H., Brannan J.D., Freed R., Andersson M., Chan H.K., Woolcock A.J., Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids, Am J Respir Crit Care Med, 163, pp. 406-412, (2001)
  • [66] Belda J., Parameswaran K., Lemiere C., Kamada D., O'Byrne P.M., Hargreave F.E., Predictors of loss of asthma control induced by corticosteroid withdrawal, Can Resp J, 13, pp. 129-133, (2006)
  • [67] Tsurikisawa N., Oshikata C., Tsuburai T., Et al., Markers for step-down of inhaled corticosteroid therapy in adult asthmatics, Allergol Int, 61, pp. 419-429, (2012)
  • [68] Rank M.A., Branda M.E., McWilliams D.B., Et al., Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program, Ann Allergy Asthma Immunol, 110, pp. 354-358, (2013)
  • [69] Zacharasiewicz A., Wilson N., Lex C., Et al., Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children, Am J Respir Crit Care Med, 171, pp. 1077-1082, (2005)
  • [70] Hoffmann H.J., Nielsen L.P., Harving H., Heinig J.H., Dahl R., Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11, Clin Respir J, 2, pp. 149-157, (2008)
234567891011